What is Premelle?
Premelle, commercialised by Wyeth-Lederle, is a combination of conjugated estrogens 0.625 mg and medroxyprogesterone acetate 5 mg which is indicated in the treatment of menopause-associated problems, among which vasomotor symptoms, atrophic vaginitis and/or urethritis, and in the prevention and treatment of post-menopausal osteoporosis. It is presented in two formulations, Premelle cyclic 5 and Premelle 5. The former, in which the progestagen is only given during the last 14 out of 28 days of the treatment cycle, is accompanied by regular bleeding and thus preferably indicated during perimenopause whereas the latter, in which the progestagen is given continuously and results in amenorrhea, is mostly indicated after menopause in order to improve long-term compliance.
Regime information for transsexuals
A combination formulation of Premarin, the only natural conjugated equine estrogens approved by FDA, and medroxyprogesterone acetate (MPA), a widely prescribed progestin.
- Ideal combination product because natural estrogen and C21 progestin are combined.
- Three regimen allows physicians to individualize HRT to suit patient needs and preferences.
- treatment of menopausal symptoms and vaginal and vulvar atrophy, prevention of osteoporosis
- moderate to severe vasomotor symptoms associated with estrogen deficiency
- Atrophic vaginitis
- Atrophic urethritis
- Prevention of osteoporosis associated with estrogen deficiency for women at high risk of fracture
PREMELLE 2.5 / 5 : To be taken once daily with 28-day cycle
PREMELLE CYCLE 5 : White tablets, to be taken on days 1 through 14 Light blue tablets, to be taken on day 15 through 28
Each blister package contains 28 tablets (also see related drug Premarin)
